Alps Advisors Inc Kodiak Sciences Inc. Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$4.81 - $8.88 $5,214 - $9,625	-1,084 Reduced 3.05%	34,462 $213,000
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.05 $46,839 - $57,831	7,184 Added 25.33%	35,546 $254,000
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $18,591 - $30,700	-2,456 Reduced 7.97%	28,362 $220,000
Q2 2022 Aug 11, 2022	SELL	$5.04 - $9.48 $113,697 - $213,859	-22,559 Reduced 42.26%	30,818 $235,000
Q1 2022 May 16, 2022	SELL	$7.09 - $89.45 $45,858 - $578,562	-6,468 Reduced 10.81%	53,377 $412,000
Q4 2021 Feb 09, 2022	SELL	$80.85 - $128.49 $260,175 - $413,480	-3,218 Reduced 5.1%	59,845 $5.07 Million
Q3 2021 Nov 15, 2021	SELL	$81.97 - $106.94 $340,667 - $444,442	-4,156 Reduced 6.18%	63,063 $6.05 Million
Q2 2021 Aug 11, 2021	BUY	$77.2 - $126.54 $5.19 Million - $8.51 Million	67,219 New	67,219 $6.25 Million
Q4 2020 Feb 03, 2021	SELL	$60.78 - $154.03 $3.47 Million - $8.78 Million	-57,021 Closed	0 $0
Q3 2020 Nov 04, 2020	SELL	$45.05 - $59.27 $164,973 - $217,046	-3,662 Reduced 6.03%	57,021 $3.38 Million
Q2 2020 Aug 05, 2020	BUY	$42.74 - $66.25 $2.59 Million - $4.02 Million	60,683 New	60,683 $3.28 Million

109

40.9M

28.4K

21.2K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $194M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.